Female body mass index and the selection of a long-acting reversible contraception for the first time.
Brazil
body mass index
contraception
long-acting reversible contraception
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
15
12
2021
received:
24
08
2021
accepted:
21
12
2021
pubmed:
24
12
2021
medline:
16
8
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
To evaluate Brazilian women with different body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) values who were switching from a short-acting reversible contraceptive (SARC) to a long-acting reversible contraceptive (LARC) method in relationship to the reasons reported for switching and the LARC method chosen. We analyzed retrospective data from 1508 women aged 18-49 years who chose a LARC for the first time. The variables were sociodemographic, BMI, SARC in use, the reason given for switching, the chosen LARC (copper intrauterine device, levonorgestrel (52 mg) intrauterine system or ethyl norgestrel implant), and expectations of the LARC. We used χ The obesity group, 320 women (21.2%), reported weight gain (P < 0.000) and fear of pregnancy (P = 0.004) as the most frequent reasons for switching, whereas the normal weight group, 637 women (42.2%), reported more loss of libido (P < 0.000) and other personal complaints (P = 0.002). The IUD was chosen by 851 women (56.6%) and significantly by the largest number of obese women. Women in different BMI categories report different reasons for switching from SARC methods and elect different LARC methods for contraception.
Substances chimiques
Contraceptive Agents, Female
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
748-753Subventions
Organisme : Brazilian National Research Council
Informations de copyright
© 2021 International Federation of Gynecology and Obstetrics.
Références
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10.
Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778):635-643.
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377-1396.
Wagner KJP, Boing AF, Cembranel F, Boing ACDS, Subramanian SV. Change in the distribution of body mass index in Brazil: analysing the interindividual inequality between 1974 and 2013. J Epidemiol Community Health. 2019;73(6):544-548.
Schraudenbach A, McFall S. Contraceptive use and contraception type in women by body mass index category. Womens Health Issues. 2009;19(6):381-389.
Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998-2007.
Morse JE, Pathak PR. Contraceptive care of obese women. Obstet Gynecol Surv. 2018;73(1):56-66.
Scott-Ram R, Chor J, Bhogireddy V, Keith L, Patel A. Contraceptive choices of overweight and obese women in a publically funded hospital: possible clinical implications. Contraception. 2012;86(2):122-126.
Ferreira JM, Nunes FR, Modesto W, Gonçalves MP, Bahamondes L. Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives. Contraception. 2014;89(1):17-21.
Pan AN, Kawachi I, Luo N, et al. Changes in body weight and health-related quality of life: 2 cohorts of US women. Am J Epidemiol. 2014;180(3):254-262.
United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive Use by Method 2019: Data Booklet (ST/ESA/SER.A/435) [UN website] 2019. Accessed October 20, 2021. https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf
Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochr Database Syst Rev. 2014;(1):CD003987.
Beksinska M, Issema R, Beesham I, et al. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: findings from a randomised, multicentre, open-label trial. EClinicalMedicine. 2021;34:100800.
Lopez LM, Ramesh S, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2016;(8):CD008815.
Bahamondes L, Brache V, Ali M, Habib N; WHO Study Group on Contraceptive Implants for Women. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement. Contraception. 2018;98(3):181-187.
Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016;(1):CD008452.
Graham CA, Ramos R, Bancroft J, Maglaya C, Farley TM. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception. 1995;52(6):363-369.
Schaffir J. Hormonal contraception and sexual desire: a critical review. J Sex Marital Ther. 2006;32(4):305-314.
Wiebe ER, Brotto LA, MacKay J. Characteristics of women who experience mood and sexual side effects with use of hormonal contraception. J Obstet Gynaecol Can. 2011;33(12):1234-1240.
Sievert LL, Morrison LA, Reza AM, Brown DE, Kalua E, Tefft HA. Age-related differences in health complaints: the Hilo women's health study. Women Health. 2007;45(3):31-51.
United Nations Foundation. Family Planning 2030. Contraceptive discontinuation: reasons, challenges, and solutions. [FP website] 2015. Accessed October 20, 2021. https://fp2030.org/resources/contraceptive-discontinuation-reasons-challenges-and-solutions
Laporte M, Metelus S, Ali M, Bahamondes L. Major differences in the characteristics of users of the copper intrauterine device or levonorgestrel intrauterine system at a clinic in Campinas, Brazil [preprint]. Int J Gynaecol Obstet. 2021;00:1-7. doi:10.1002/ijgo.13716
Gemzell-Danielsson K, Kubba A, Caetano C, Faustmann T, Lukkari-Lax E, Heikinheimo O. Thirty years of Mirena: a story of innovation and change in women’s healthcare. Acta Obstet Gynecol Scand. 2021;100(4):614-618.
MacKintosh ML, Crosbie EJ. Prevention strategies in endometrial carcinoma. Curr Oncol Rep. 2018;20(12):101.
De Nadai MN, Vieira CS, Monteiro IMU, et al. Practical training of health care providers in insertion of contraceptive implants: findings from two Brazilian centres. Eur J Contracept Reprod Health Care. 2021;26(6):499-502.